US biotech firm bluebird bio (Nasdaq: BLUE) on Friday officially opened its first wholly-owned manufacturing facility in Durham, North Carolina, that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease.
Analysts think bb2121 could gain approval by 2020 and hit peak sales of $5 billion, leading a crowded CAR-T field in the disease. LentiGlobin worldwide revenues could exceed $800m in worldwide revenue in TDT.
Currently, bluebird employs around 50 scientists, engineers, manufacturing and operations personnel at the facility and is on track to grow to about 70 employees by the end of 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze